Related references
Note: Only part of the references are listed.Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study
Monika Francz et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations
Yun Gong et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Automated Cellular Imaging System III for Assessing HER2 Status in Breast Cancer Specimens Development of a Standardized Scoring Method That Correlates With FISH
Douglas M. Minot et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Emerging Technologies for Assessing HER2 Amplification
Frederique Penault-Llorca et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results
Yun Gong et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Combined effects of formalin fixation and tissue processing on immunorecognition
D Otali et al.
BIOTECHNIC & HISTOCHEMISTRY (2009)
Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization
Doris Mayr et al.
HISTOPATHOLOGY (2009)
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
Guido Sauter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Using a higher cutoff for the percentage of HER2+cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis
Omar Hameed et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
Omar Hameed et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer
Ruoyu Ni et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2007)
Chromogenic and fluorescent in situ hybridization in breast cancer
Maryou B. K. Lambros et al.
HUMAN PATHOLOGY (2007)
A novel method for multiple labeling combining in situ hybridization with immunofluorescence
Isabelle Pineau et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2006)
Analytical validation and interobserver reproducibility of EnzMet GenePro - A second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast
E Downs-Kelly et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Immunohistochemical stains for p63 and α-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma -: A comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues
O Hameed et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
HER-2 testing in breast cancer using parallel tissue-based methods
H Yaziji et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Share Paper
